Glaxo challenges $2.7 billion transfer pricing claim
GlaxoSmithKline Holdings on April 2 2004 filed a petition in the US Tax Court contesting a multibillion-dollar transfer pricing claim. The US Internal Revenue Service (IRS) made its claim in January against Glaxo US, a US subsidiary of the UK-based pharmaceutical manufacturer GlaxoSmithKline.
To access our market-driven intelligence please request a trial here.
Read this article – and more – for a 30 day period.